Rocket Pharmaceuticals (RCKT) Convertible Debt (2015 - 2021)

Rocket Pharmaceuticals (RCKT) has 7 years of Convertible Debt data on file, last reported at $35.5 million in Q1 2021.

• For the quarter ending Q1 2021, Convertible Debt fell 22.38% year-over-year to $35.5 million; the trailing twelve-month figure through Mar 2021 stood at $35.5 million (down 22.38% YoY), and the FY2020 full-year result was $35.1 million, down 22.16% from the prior year.
• Convertible Debt grew to $35.5 million in Q1 2021, from $35.1 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $49.4 million in Q3 2017 to a low of $35.1 million in Q4 2020.
• A 5-year average of $43.0 million and a median of $42.7 million in 2019 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt advanced 8.69% in 2019 and retreated 22.38% in 2021, its largest moves.
• Tracing RCKT's Convertible Debt over 5 years: stood at $49.4 million in 2017, then slipped by 16.08% to $41.4 million in 2018, then gained by 8.69% to $45.0 million in 2019, then slipped by 22.16% to $35.1 million in 2020, then increased by 1.36% to $35.5 million in 2021.
• Business Quant data shows RCKT's Convertible Debt at $35.5 million in Q1 2021, $35.1 million in Q4 2020, and $42.1 million in Q3 2020.